Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib Rollover Study in Advanced or Metastatic Solid Malignancies
NCT04887870Phase 3Completed
- Sponsor
- Mirati Therapeutics
- Start
- Jun 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sitravatinib in solid malignancy, sponsored by Mirati Therapeutics. Started Jun 2021; status: completed.
02
Drugs
sitravatinib
03
Conditions
solid malignancy
Beyond the preview
Go deeper on NCT04887870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887870.